Polyionic Papilloma Virus-like Particle (VLP) Vaccines

Case ID:
C11195
Disclosure Date:
7/30/2010
Description:
Value Proposition:
-Attractive vaccine candidates that are not infectious and have self-assembling properties.
-Vaccine particles can accommodate a wide range of antigens in terms of size and composition.
-Antigens may be loaded onto pre-formed vaccine particles without interfering with the self- assembling properties of the carrier.
-The present technology can elicit a strong cytotoxic T cell response in absence of adjuvant.
 
Technical Details:
JHU scientists have developed a generic platform technology for vaccines based on chimeric papillomavirus VLPs. The potential use of this technology in developing vaccines for cancer and infectious diseases (eg. malaria; dengue, and SARS). This technology may be further developed to have application in areas particularly where it is desirable to induce CD8 T cell responses.
Why we need T cell vaccines
 
Looking for Partners:
This technology may be developed as a vaccine for various conditions
 
Publications/Associated Cases:
Pejawar-Gaddy et al (2010) Generation of a Tumor Vaccine Candidate Based on Conjugation of a MUC1 Peptide to Polyionic Papillomavirus Virus-Like Particles (VLPs). Cancer Immunol Immunother. 59(11): 1685–1696
WO2012033911
 
Patent Information:
Inventors:
Category(s):
For Information, Contact:
Nakisha Holder
nickki@jhu.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum